Clinical observation of raltitrexed containing regimen for advanced colorectal cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 583-586, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-659458
ABSTRACT
Objective To observe the clinical efficacy and adverse reactions of raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment.Methods A total of 42 patients with advanced colorectal cancer were treated with raltitrexed containing regimen.The objective response rate (ORR),disease control rate (DCR),median progression-free survival (mPFS) and adverse reactions were evaluated.Results The ORR of the 42 patients was 16.67%,DCR was 80.96%,and mPFS was 4.90 months (95% CⅠ2.99-6.81 months).The most of adverse reactions were grade Ⅰ-Ⅱ,including leucopenia (30.95%),thrombocytopenia (2.38%),anemia (40.48%),nausea and vomiting (2.38%),anorexia (4.76%),diarrhea (2.38%),transaminase elevation (47.62%) and fatigue (11.90%).Grade Ⅲ-Ⅳ transaminase elevation was found in only 4.76% of patients.Conclusion Raltitrexed containing regimen for advanced colorectal cancer as the second-line and multi-line treatment is effective and well tolerated,and further clinical application is recommended.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS